Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Galderma approved for Differin(R) Gel 0.1 percent in Japan
Lausanne, Switzerland - Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).
Lausanne, Switzerland
- Galderma Pharma S.A. announced that Japan’s Health Labor and Welfare has approved Differin(R) Gel 0.1 percent (adapalene).
The drug, used to treat acne vulgaris, will be marketed in Japan by Galderma KK, the Japanese arm of Galderma.
Related Videos
Related Content
